VF arrest secondary to immune checkpoint inhibitor (ICI)-associated myocarditis; improving patient outcomes by maintaining a high clinical suspicion for ICI toxicity
Introduction: Use of immune checkpoint inhibitor (ICI) medications has revolutionised clinical outcomes and remains an exciting prospect in oncology as further indications are revealed.1 However, adverse effects, or toxicities, secondary to their non-targeted immunological activation create an array...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2025-07-01
|
| Col·lecció: | Clinical Medicine |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1470211825002015 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|